News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Draft "Yes" for Astellas Pharma Inc. (ALPMY)' Prostate Cancer Drug


10/18/2013 8:12:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) for treating hormone relapsed metastatic prostate cancer. Xtandi is an effective treatment and, as it can be taken orally, it allows patients to be treated at home, said Professor Carole Longson, director of NICE’s Centre for Health Technology Evaluation. Xtandi works in a different way to other drugs currently available for prostate cancer treatment. NICE’s draft guidance recommends it as an option for treating hormone relapsed prostate cancer in adults, only if their disease has progressed during or after one docetaxel-containing chemotherapy regimen and if the manufacturer provides it with the discount agreed in the patient access scheme (PAS).

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES